A phase I study of combined docetaxel and repeated high activity Re-186-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial)
| Data(s) |
01/11/2011
|
|---|---|
| Resumo |
Purpose Bone-seeking radiopharmaceuticals have palliative benefit in castration-resistant prostate cancer (CRPC) metastatic to bone. Recent studies have shown improvement of survival and quality of life when radiopharmaceuticals were given repeatedly or in combination with chemotherapy. We designed a phase I study combining docetaxel and Re-186-labelled hydroxyethylidene diphosphonate (HEDP) in men with CRPC and bone metastases to evaluate toxicity. |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Van Dodewaard-de Jong , J M , De Klerk , J M H , Bloemendal , H J , Van Bezooijen , B P J , De Haas , M J , Wilson , R & O'Sullivan , J 2011 , ' A phase I study of combined docetaxel and repeated high activity Re-186-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial) ' European Journal of Nuclear Medicine and Molecular Imaging , vol 38 , no. 11 , pp. 1990-1998 . DOI: 10.1007/s00259-011-1883-0 |
| Palavras-Chave | #/dk/atira/pure/subjectarea/asjc/2700/2741 #Radiology Nuclear Medicine and imaging |
| Tipo |
article |
